Part of the raison d’etre of #StockMarketWatch is to fill in the gaps left by the mainstream media.
Pharma services specialist Open Orphan (ORPH) announced that its subsidiary hVIVO has been selected to lead a consortium, on behalf of HIC-Vac, an international network of researchers who are developing human infection challenge studies to accelerate the development of vaccines against pathogens, and the Wellcome Trust, to generate regulatory style guidelines on the manufacture of human challenge agents for subsequent use in controlled human infection studies. The shares settled at 23.5p after the latest in a series of solid newsflow for the company.
Shares of clinical stage biotechnology company Tiziana Life Sciences (TILS) rose for the second day, this time by 11%. Helping drive sentiment was a positive read across in the wake of encouraging results from Roche’s Actemra arthritis drug, which provided a positive read across for Tiziana’s anti IL-6 drug TZLS-501, which is substantially more potent.
Vela (VELA), which last month managed to transform itself into a COVID-19 play, was said to be the subject of “background buying”, with the shares holding near the floor of the recent range around 0.07p. Traders were suggesting that the result of the recent stock churn for the company which is sitting on an economic interest in a late-stage Phase II therapeutic project to develop a potential coronavirus treatment for diabetics, would be a significant TR1 / stakebuilding announcement.
Shares of Surrey focused resources play UK Oil & Gas (UKOG) edged up off recent lows, with a 0.08p gain to 0.17p. There was talk that buying in the stock could return ahead of the company’s Loxley gas appraisal planning application. This was after Surrey County Council confirmed to UKOG that the rerun of this (NIMBY) exercise was scheduled for 27th November 2020.
There was good news for Bluejay Mining (JAY) and perhaps everyone else in the country, as it announced that the First-Tier Tribunal (Tax Chamber) has, on 18 November 2020, delivered its decision to allow the Company’s appeal against HMRC’s 2016 decisions to deny it credit for input VAT. Shares of the Greenland and Finland exploration and development company edged up 0.075p to 10.5p.
Shares of minerals and exploration group, Alien Metals (UFO) were on the front foot with a 0.2p to 1.32p. The gain was after a period of consolidation for the shares. Interestingly enough, the main official impetus for the stock rise was the announcement by the company of a new website to show off its portfolio and update its recent projects.
The battle between the bears and bulls was at its most active surrounding Remote Monitored Systems (RMS), with the stock closing around at the 2.7p after a probe below 2.5p. Traders were apparently caught between bottom fishing the anti-viral face mask play, with recent COVID-19 vaccine developments, and the departure of Braveheart (BRH) as a stakeholder earlier in the week at 2.66p. Braveheart announced it had netted another approx. £3m from its investment in RMS.
Shares of Omega Diagnostics (ODX) continued their attempt at rehabilitation, with a 3p rise to 55p. This was in the wake of the announcement from the diagnostics company earlier this week regarding a press release by the UK Rapid Test Consortium of which Omega Diagnostics is a partner. The press release announced that Abingdon Health had received confirmation from the FDA in the US that the notification process for Coronavirus Disease Tests had been completed.
(The opinions expressed here are those of the author, a columnist for Share Talk.)
Zakmir.com is a purely journalistic website – Zak Mir is a member of the National Union of Journalists. There is no intention here of providing financial advice. It is recommended you seek an independent professional opinion before deciding whether or not to take any action with regard to anything written here.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned